Clinical study using MedicQuant technology presented at ESOC 2026

In May 2026, MedicQuant participated at the 2026 European Stroke Organisation Conference (ESOC) in Maastricht, the Netherlands where presented study demonstrated that MedicQuant's technology is the first point-of-care test to deliver results comparable to laboratory-based quantitative assessment of apixaban plasma.

Specifically, the study showed that MedicQuant's technology enables feasible quantitative assessment of apixaban plasma concentrations up to 200 ng/mL, supporting its comparability to laboratory-based calibrated factor-Xa activity.

It was a great experience to meet and talk with all the professionals in the field to discuss all the exciting developments that are happening in the field right at this moment. We were especially happy to be able to contribute to these discussions by sharing our promising results with the world!